Inhibitory effect of vitamin D-binding protein‑derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line

Toyohara,Yukiyo; Hashitani,Susumu; Kishimoto,Hiromitsu; Noguchi,Kazuma; Yamamoto,Nobuto; Urade,Masahiro

doi:10.3892/ol.2011.306

Inhibitory effect of vitamin D-binding protein‑derived macrophage activating factor on DMBA-induced hamster cheek pouch carcinogenesis and its derived carcinoma cell line

Authors:
- Yukiyo Toyohara
- Susumu Hashitani
- Hiromitsu Kishimoto
- Kazuma Noguchi
- Nobuto Yamamoto
- Masahiro Urade
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan, Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, PA 19126-3305, USA
Published online on: May 13, 2011 https://doi.org/10.3892/ol.2011.306
Pages: 685-691

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study investigated the inhibitory effect of vitamin D-binding protein-derived macrophage-activating factor (GcMAF) on carcinogenesis and tumor growth, using a 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced hamster cheek pouch carcinogenesis model, as well as the cytocidal effect of activated macrophages against HCPC-1, a cell line established from DMBA-induced cheek pouch carcinoma. DMBA application induced squamous cell carcinoma in all 15 hamsters of the control group at approximately 10 weeks, and all 15 hamsters died of tumor burden within 20 weeks. By contrast, 2 out of the 14 hamsters with GcMAF administration did not develop tumors and the remaining 12 hamsters showed a significant delay of tumor development for approximately 3.5 weeks. The growth of tumors formed was significantly suppressed and none of the hamsters died within the 20 weeks during which they were observed. When GcMAF administration was stopped at the 13th week of the experiment in 4 out of the 14 hamsters in the GcMAF-treated group, tumor growth was promoted, but none of the mice died within the 20-week period. On the other hand, when GcMAF administration was commenced after the 13th week in 5 out of the 15 hamsters in the control group, tumor growth was slightly suppressed and all 15 hamsters died of tumor burden. However, the mean survival time was significantly extended. GcMAF treatment activated peritoneal macrophages in vitro and in vivo, and these activated macrophages exhibited a marked cytocidal effect on HCPC-1 cells. Furthermore, the cytocidal effect of activated macrophages was enhanced by the addition of tumor-bearing hamster serum. These findings indicated that GcMAF possesses an inhibitory effect on tumor development and growth in a DMBA-induced hamster cheek pouch carcinogenesis model.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Von Dongen GA and Snow GB: Prospectives for future studies in head and neck cancer. Eur J Surg Oncol. 23:485–491. 1997.
3	Gross L: Immunological defect in aged population and its relationship to cancer. Cancer Res. 18:201–204. 1965.PubMed/NCBI
4	Ngwenya BZ and Yamamoto N: Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta. 839:9–15. 1985. View Article : Google Scholar : PubMed/NCBI
5	Yamamoto N, Naraparaju VR and Urade M: Prognostic utility of serum α-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res. 57:295–299. 1997.
6	Yamamoto N and Hoober JK: Tumoricidal capacities of macrophages photodynamically activated with hematoporphyrin derivative. Photochem Photobiol. 56:245–250. 1992. View Article : Google Scholar : PubMed/NCBI
7	Fidler JJ and Schroit AJ: Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta. 948:151–173. 1988.PubMed/NCBI
8	Keller R: The macrophage response to infectious agents: mechanisms of macrophage activation and tumor cell killing. Res Immunol. 144:271–273. 1993. View Article : Google Scholar : PubMed/NCBI
9	Klostergard J: Macrophage tumoricidal mechanisms. Res Immunol. 144:274–276. 1993. View Article : Google Scholar
10	Yamamoto N and Naraparaju VR: Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res. 57:2187–2192. 1997.PubMed/NCBI
11	Yamamoto N, Suyama H, Nakazato H, Yamamoto NY and Koga Y: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage activating factor, GcMAF. Cancer Immunol Immunother. 57:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yamamoto N, Suyama H, Yamamoto NY and Ushijima N: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer. 122:461–467. 2008. View Article : Google Scholar : PubMed/NCBI
13	Yamamoto N, Suyama H and Yamamoto N: Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol. 1:65–72. 2008. View Article : Google Scholar : PubMed/NCBI
14	Yamamoto N, Willett NP and Lindsay DD: Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation. 18:311–322. 1994. View Article : Google Scholar : PubMed/NCBI
15	Link RP, Perlman KL, Pierce EA, Schnoes HK and DeLuca HF: Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal Biochem. 157:262–269. 1986. View Article : Google Scholar : PubMed/NCBI
16	Yamamoto N and Kumashiro R: Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. J Immunol. 151:2794–2802. 1993.
17	Yamamoto N: Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production. Mol Immunol. 33:1157–1164. 1996. View Article : Google Scholar
18	Nishimura N, Urade M, Hashitani S, et al: Increased expression of cyclooxygenase (COX)-2 protein in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med. 33:614–621. 2004. View Article : Google Scholar : PubMed/NCBI
19	Segawa E, Hashitani S, Toyohara Y, et al: Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch carcinogenesis and its derived cell line. Oncol Rep. 21:869–874. 2009.PubMed/NCBI
20	Odukoya O, Schwartz J, Weichselbaum R and Shklar G: An epidermoid carcinoma cell line derived from hamster 7,12-dimethylbenz(α)anthracene-induced buccal pouch tumors. J Natl Cancer Inst. 71:1253–1264. 1983.
21	Zbar B and Tanaka T: Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science. 172:271–273. 1971. View Article : Google Scholar : PubMed/NCBI
22	Morton D, Eibler FR, Malmgren RA and Wood WC: Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 68:158–164. 1970.PubMed/NCBI
23	Yamamoto N and Ngwenya BZ: Activation of mouse peritoneal macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids. Cancer Res. 47:2008–2013. 1987.PubMed/NCBI
24	Yamamoto N, Ngwenya BZ and Pieringer PA: Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol Immunother. 25:185–192. 1987. View Article : Google Scholar : PubMed/NCBI
25	Yamamoto N, St Claire DA Jr, Homma S and Ngwenya BZ: Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res. 48:6044–6049. 1988.PubMed/NCBI
26	Homma S and Yamamoto N: Activation process of macrophage after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol. 79:307–313. 1990. View Article : Google Scholar : PubMed/NCBI
27	Homma S, Yamamoto M and Yamamoto N: Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol. 71:249–257. 1993. View Article : Google Scholar
28	Naraparaju VR and Yamamoto N: Roles of beta-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett. 43:143–148. 1994. View Article : Google Scholar : PubMed/NCBI
29	Yamamoto N and Homma S: Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA. 88:8539–8543. 1991. View Article : Google Scholar
30	Yamamoto N, Homma S, Haddad JG and Kowalski MN: Vitamin D3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunology. 74:420–424. 1991.PubMed/NCBI
31	Yamamoto N, Homma S and Millman I: Identification of the serum factor required for in vitro activation of macrophage – role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol. 147:273–280. 1991.PubMed/NCBI
32	Zhang S, Cordon-Cardo C, Zhang HS, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry. I Focus on gangliosides. Int J Cancer. 73:42–49. 1997. View Article : Google Scholar : PubMed/NCBI
33	Zhang S, Zhang HS, Cordon-Cardo C, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry. II Blood group-related antigens. Int J Cancer. 73:50–56. 1997. View Article : Google Scholar : PubMed/NCBI
34	Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G and Livingston PO: Selection of tumor antigens as targets for immune attack using immunohistochemistry. III Protein antigen. Clin Cancer Res. 4:2669–2676. 1998.PubMed/NCBI
35	Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y and Livingston PO: Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer. 97:660–667. 2002. View Article : Google Scholar : PubMed/NCBI
36	Ngwenya BZ and Yamamoto N: Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother. 21:174–182. 1986. View Article : Google Scholar : PubMed/NCBI
37	Yamamoto N, Urade M and Ueda M: Potent tumoricidal capacity of macrophages activated by Gc protein-derived macrophage activating factor (GcMAF) and its therapeutic efficacy for prostate, breast and colorectal cancers. J Immunother. 28:6422005. View Article : Google Scholar
38	Yamamoto N and Ueda M: Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology. Medmond Ltd; Bologna, Italy: pp. 201–204. 2004